49 Summary/Description of PV Systems and Risk-Based Inspections Companies doing business or clinical trials in the European Union must prepare and have on file a critical document known as the…
38 Pharmaceutical Companies There are many types of companies and institutions in the pharmaceutical world with responsibilities regarding drug safety. A summary of various types of institutions follows. There are…
28 Data Privacy and Security Approximately 30 or so years ago, with the advent of enormous changes in communication, personal computers, and medicine and society (greater mobility, the ascent of…
14 Coding of AEs and Drug Names As pharmacovigilance becomes more mechanized and computerized, the need for standard terminologies, formats, dictionaries, narratives, and abbreviations grows. The first two major areas…
5 Adverse Events with New Chemical Entities, Generics, Excipients, Placebos, and Counterfeits Are some adverse events (AEs) created more equal than others? Are some AEs more important than others? Why…
31 The United States FDA’s Three Risk Guidances of 2005 In March 2005, the U.S. Food and Drug Administration (FDA) issued three guidances, which were years in the making, summarizing…
33 Product Quality Issues In the past several years, it has been realized that many other issues in addition to bad reactions to the active chemical entity in the product…
2 Clinical Trials, Clinical Research Organizations, Phases I–IV, and Investigator-Initiated Trials To obtain approval to market a new drug in the United States, Canada, the European Union, and most other…
23 The Qualified Person for Pharmacovigilance For companies with products sold in the European Union, Volume 9A requires that there be a “Qualified Person for Pharmacovigilance” (QPPV or QP). This…
54 Real-World Issues: Nomifensine Nomifensine (Merital) was first used as an antidepressant in Germany in 1976, in the United Kingdom in 1977, and in the United States in 1985. From…
